![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() by Staff Writers Sao Paulo (AFP) July 21, 2020
Brazil will begin advanced clinical testing of a Chinese-made vaccine against the new coronavirus Tuesday, issuing the first doses to around 900 volunteers, officials said. The coronavirus vaccine, developed by private Chinese pharmaceutical firm Sinovac, is the third in the world to enter Phase 3 trials, or large-scale testing on humans -- the last step before regulatory approval. It will be administered to doctors and other health workers who volunteer for the program across six states in Brazil, one of the countries hit hardest by the pandemic. "Trials of CoronaVac, one of the vaccines that has advanced furthest in testing in the world, will begin at the Clinical Hospital of Sao Paulo," the state's governor, Joao Doria, told a news conference. He said initial results were expected within 90 days. Sinovac is partnering with a Brazilian public health research center, the Butantan Institute, on the trials. If the vaccine proves safe and effective, the institute will have the right to produce 120 million doses under the deal, according to officials. "In Brazil, we could have the first vaccine to be put to widespread use, which is very, very promising," said the head of the Butantan Institute, Dimas Covas. Brazil is the second-hardest-hit country in the coronavirus pandemic, after the United States. Its death toll surpassed 80,000 on Monday, and it has registered 2.1 million infections. Those grim figures make it an ideal testing ground for potential vaccines, since the virus is still spreading quickly. Brazil is also helping carry out Phase 3 testing of another experimental vaccine, developed by Oxford University in Britain and pharmaceutical firm AstraZeneca. Another vaccine, developed by state-owned Chinese company Sinopharm, also entered Phase 3 trials this month in the United Arab Emirates. They are the three most advanced of the dozens of projects worldwide by scientists racing to develop and test a vaccine against the new virus. A fourth, existing vaccine against tuberculosis is also in Phase 3 trials in Australia as a potential coronavirus immunization. val/jhb/to
![]() ![]() Millions face new virus curbs, but hope rises for US vaccine Hong Kong (AFP) July 15, 2020 Millions of people faced new coronavirus restrictions on Wednesday as infections surge, but in one sign of hope, an American firm said it would soon start final-stage human trials for a possible vaccine. Countries around the world re-imposed lockdowns and curbs to contain new outbreaks, as global cases surged past 13.2 million with more than 576,000 deaths. Parts of the Asia-Pacific region, which had been somewhat successful in fighting the pandemic, provided fresh evidence of the deadly threat ... read more
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |